What is the 13F Pro Quality Score for NKTX?

13F Pro ranks Nkarta, Inc. (NKTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NKTX's current score at https://13fpro.ai/research/NKTX (free sign-up required for the full ranking).

Which hedge funds own the most NKTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NKTX include RA CAPITAL MANAGEMENT, L.P., BlackRock,, NEA Management Company,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NKTX as soon as new 13F filings post.

Where does 13F Pro source NKTX data?

All Nkarta, Inc. fundamentals and ownership data come directly from SEC EDGAR. Nkarta, Inc. files with the SEC under CIK 1787400. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NKTX in?

Nkarta, Inc. (NKTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NKTX research updated on 13F Pro?

NKTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Nkarta, Inc.(NKTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1787400 NKTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NKTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Nkarta, Inc. (NKTX), a Healthcare sector company. NKTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Nkarta, Inc. reports net income of $-27.8M, free cash flow of $-28.6M. Top institutional holders of NKTX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock,, NEA Management Company,, based on the most recent SEC filings. NKTX trades on the Nasdaq exchange and files with the SEC under CIK 1787400. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nkarta, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-27.8M

Free Cash Flow

Q1 2026

$-28.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY21 $0.00FY22 —FY23 —FY25 $0.00

Net Income

+11.4% YoY

$-104.1MFY 2025

FY21 $-86.1MFY22 $-113.8MFY23 $-117.5MFY25 $-104.1M

Operating Income

+7.3% YoY

$-122.0MFY 2025

FY21 $-86.4MFY22 $-119.0MFY23 $-131.7MFY25 $-122.0M

EPS (Diluted)

+41.3% YoY

$-1.41FY 2025

FY21 $-2.62FY22 $-2.61FY23 $-2.40FY25 $-1.41

Total Assets

+6.7% YoY

$404.2MFY 2025

FY21 $273.9MFY22 $472.9MFY23 $378.9MFY25 $404.2M

Op. Cash Flow

-2.9% YoY

$-88.7MFY 2025

FY21 $-67.9MFY22 $-57.0MFY23 $-86.2MFY25 $-88.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$0.00	—	—	$0.00 -100.0%	$115.0K
Net Income	$-104.1M +11.4%	$-117.5M -3.2%	$-113.8M -32.3%	$-86.1M -308.4%	$-21.1M
Operating Income	$-122.0M +7.3%	$-131.7M -10.7%	$-119.0M -37.6%	$-86.4M -286.7%	$-22.3M
EPS (Diluted)	$-1.41 +41.3%	$-2.40 +8.0%	$-2.61 +0.4%	$-2.62	—
Total Assets	$404.2M +6.7%	$378.9M -19.9%	$472.9M +72.7%	$273.9M +465.8%	$48.4M
Operating Cash Flow	$-88.7M -2.9%	$-86.2M -51.2%	$-57.0M +16.1%	$-67.9M -269.8%	$-18.4M

AI Insight: NKTX Financial Trends

Nkarta continues burning through equity at ~$25M/quarter with no revenue, leaving roughly $286M in equity — a finite runway for a pre-commercial biotech.

• Equity has declined every quarter from $453M in Q2 2024 to $286M in Q1 2026, a cumulative erosion of $167M over eight quarters.

• Operating cash burn moderated from -$30M in Q1 2025 to -$19M in Q2–Q3 2025, before re-widening to -$28M in Q1 2026.

• No revenue recorded across all eight quarters; the company remains entirely pre-commercial with zero top-line contribution.

⚠ At the Q1 2026 burn rate of -$28M operating CF, remaining equity of $286M implies roughly 10 quarters of runway absent new financing.

⚠ Op losses re-accelerated to -$31M in Q4 2025 and Q1 2026 after a brief narrowing to -$27M in Q2–Q3 2025 — watch for sustained cost control.

⚠ No debt reported across all periods; any introduction of debt financing would signal a meaningful shift in capital structure.

AI Insight: NKTX Ratio Trends

All three return metrics are deteriorating sharply, with ROIC hitting -43.2% in Q1 2026 — the worst reading in the dataset.

• ROIC worsened from -27.1% in Q2 2024 to -43.2% in Q1 2026, a 16pp deterioration over roughly seven quarters.

• ROA declined from -18.0% in Q2 2024 to -29.9% in Q1 2026, signaling accelerating asset-base inefficiency.

• ROE deepened from -22.1% in Q2 2024 to -38.9% in Q1 2026, reflecting mounting equity erosion as losses compound.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods — critical gaps that obscure cost structure and leverage risk.

⚠ Q1 2026 ROIC of -43.2% marks a sequential deterioration from -39.6% in Q4 2025 — trend is accelerating, not stabilizing.

Get alerted when NKTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Nkarta, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NKTX

RA CAPITAL MANAGEMENT, L.P.
$22.8M10,805,129 sh
BlackRock, Inc.
$9.5M4,508,473 sh
NEA Management Company, LLC
$7.5M3,568,781 sh
Samsara BioCapital, LLC
$7.4M3,507,666 sh
SR ONE CAPITAL MANAGEMENT, LP
$7.0M3,333,333 sh
GSK plc
$6.6M3,150,732 sh
Monaco Asset Management SAM
$5.3M2,521,932 sh
Alyeska Investment Group, L.P.
$4.4M2,084,840 sh
TWO SIGMA INVESTMENTS, LP
$4.3M2,047,376 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.2M2,011,421 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$22.8M	10,805,129
BlackRock, Inc.	$9.5M	4,508,473
NEA Management Company, LLC	$7.5M	3,568,781
Samsara BioCapital, LLC	$7.4M	3,507,666
SR ONE CAPITAL MANAGEMENT, LP	$7.0M	3,333,333
GSK plc	$6.6M	3,150,732
Monaco Asset Management SAM	$5.3M	2,521,932
Alyeska Investment Group, L.P.	$4.4M	2,084,840
TWO SIGMA INVESTMENTS, LP	$4.3M	2,047,376
VANGUARD CAPITAL MANAGEMENT LLC	$4.2M	2,011,421

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NKTX on your watchlist

Track score changes the day Nkarta, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NKTX a good stock to buy?

13F Pro's AI-powered analysis of Nkarta, Inc. (NKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NKTX are available on the NKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NKTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nkarta, Inc.'s investment landscape.